Dark
Streaming/Mobile
Old Site
Home
Daily
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:37:33 EDT Mon 27 Mar 2023
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:LXRX from 2022-03-28 to 2023-03-27 - 34 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2023-03-04 12:00
U
U:LXRX
News Release
200
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology ¢ € ™s 72nd Annual Scientific Session Together With World Heart Federation ¢ € ™s World Congress of Cardiology
2023-03-04 10:00
U
U:LXRX
News Release
200
Lexicon Reveals ¢ € œINTO THE DARK ¢ € Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
2023-03-02 16:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
2023-02-28 17:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
2023-02-20 08:00
U
U:LXRX
News Release
200
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology ¢ € ™s 72nd Annual Scientific Session Together With World Heart Federation ¢ € ™s World Congress of Cardiology
2023-01-06 16:05
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
2022-12-21 16:30
U
U:LXRX
News Release
200
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
2022-11-28 08:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
2022-11-14 16:03
U
U:LXRX
News Release
200
Lexicon ¢ € ™s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
2022-11-11 08:58
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
2022-11-09 16:01
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
2022-11-08 08:58
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit
2022-11-06 17:29
U
U:LXRX
News Release
200
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure
2022-11-05 10:35
U
U:LXRX
News Release
200
New Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
2022-11-04 08:58
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
2022-10-31 08:59
U
U:LXRX
News Release
200
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
2022-10-24 08:59
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
2022-10-02 13:00
U
U:LXRX
News Release
200
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events
2022-09-20 08:59
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
2022-08-22 16:05
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
2022-08-05 16:59
U
U:LXRX
News Release
200
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
2022-08-02 16:01
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
2022-07-29 08:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
2022-07-28 07:00
U
U:LXRX
News Release
200
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
2022-07-27 16:01
U
U:LXRX
News Release
200
Lexicon Announces Proposed Public Offering Of Common Stock
2022-07-27 07:59
U
U:LXRX
News Release
200
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
2022-06-29 16:01
U
U:LXRX
News Release
200
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
2022-06-01 08:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
2022-05-31 08:00
U
U:LXRX
News Release
200
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
2022-05-05 06:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
2022-04-29 08:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
2022-04-07 08:00
U
U:LXRX
News Release
200
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
2022-04-04 08:00
U
U:LXRX
News Release
200
Lexicon Welcomes New Guidelines for the Management of Heart Failure
2022-04-02 12:15
U
U:LXRX
News Release
200
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)